Network pharmacology integrated with experimental validation reveals the regulatory mechanism of action of Hehuan Yin decoction in polycystic ovary syndrome with insulin resistance.
J Ethnopharmacol. 2022 May 10; 289:115057.JE

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE

Hehuan Yin decoction (HHY), first recorded in the Jingyue Quanshu (published in 1624 A.D.), is composed of Albizia julibrissin Durazz. and Ampelopsis japonica (Thunb.) Makino.

AIM OF THE STUDY

This study aimed to investigate the mechanism of action of HHY in treating polycystic ovary syndrome with insulin resistance (PCOS-IR).

MATERIALS AND METHODS

Network pharmacology and molecular docking were used to predict active compounds, potential targets, and pathways for PCOS-IR treatment using HHY. Female Sprague-Dawley rats were administered letrozole (1 mg/kg) with a high-fat diet to establish a PCOS-IR model. Thereafter, symptoms, ovarian pathology, serum insulin resistance, and sex hormone levels were determined. Western blotting was used to determine the levels of PI3Kp85α, AKT, phospho (p)-AKT, and GSK3β in the ovaries of rats.

RESULTS

Network pharmacology revealed 58 components in HHY and 182 potential targets that were shared between HHY and PCOS-IR. HHY could potentially treat PCOS-IR via the insulin resistance, PI3K/AKT, HIF-1, and steroid hormone biosynthesis pathways. Molecular docking revealed that PI3K, AKT1, GSK3β, IRS1, and EGFR had high affinities to HHY compounds. In the PCOS-IR rats, HHY significantly normalised the symptoms and ovarian pathology, increased follicle-stimulating hormone (FSH) and oestradiol levels in the serum, and decreased the levels of fasting plasma glucose and fasting insulin, as well as the insulin resistance index. HHY also decreased the luteinising hormone (LH) and testosterone levels and the LH/FSH ratio in the PCOS-IR rats and increased the levels of PI3K, p-AKT, and GSK3β in ovary tissue, which indicated the activation of the PI3K/AKT pathway.

CONCLUSIONS

HHY can improve PCOS-IR symptoms via multiple pharmacological pathways and may be a potential alternative therapy for the treatment of PCOS-IR.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Wu YY

School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 510515, China; Guangdong Provincial Key Laboratory of Chinese Medicine Pharmaceutics, Guangzhou, 510515, China; Guangdong Provincial Engineering Laboratory of Chinese Medicine Preparation Technology, Guangzhou, 510515, China.

MeSH

AnimalsDiet, High-FatDisease Models, AnimalDrugs, Chinese HerbalFemaleInsulin ResistanceLetrozoleMolecular Docking SimulationNetwork PharmacologyPhosphatidylinositol 3-KinasePolycystic Ovary SyndromeProto-Oncogene Proteins c-aktRatsRats, Sprague-Dawley

Pub Type(s)

Journal Article

Validation Study

Language

eng

PubMed ID

35121050

Citation

Wu, Yuan-Yuan, et al. "Network Pharmacology Integrated With Experimental Validation Reveals the Regulatory Mechanism of Action of Hehuan Yin Decoction in Polycystic Ovary Syndrome With Insulin Resistance." Journal of Ethnopharmacology, vol. 289, 2022, p. 115057.

Wu YY, Li SY, Zhu HQ, et al. Network pharmacology integrated with experimental validation reveals the regulatory mechanism of action of Hehuan Yin decoction in polycystic ovary syndrome with insulin resistance. J Ethnopharmacol. 2022;289:115057.

Wu, Y. Y., Li, S. Y., Zhu, H. Q., Zhuang, Z. M., Shao, M., Chen, F. L., Liu, C. S., & Tang, Q. F. (2022). Network pharmacology integrated with experimental validation reveals the regulatory mechanism of action of Hehuan Yin decoction in polycystic ovary syndrome with insulin resistance. Journal of Ethnopharmacology, 289, 115057. https://doi.org/10.1016/j.jep.2022.115057

Wu YY, et al. Network Pharmacology Integrated With Experimental Validation Reveals the Regulatory Mechanism of Action of Hehuan Yin Decoction in Polycystic Ovary Syndrome With Insulin Resistance. J Ethnopharmacol. 2022 May 10;289:115057. PubMed PMID: 35121050.

* Article titles in AMA citation format should be in sentence-case

TY - JOUR T1 - Network pharmacology integrated with experimental validation reveals the regulatory mechanism of action of Hehuan Yin decoction in polycystic ovary syndrome with insulin resistance. AU - Wu,Yuan-Yuan, AU - Li,Shu-Yu, AU - Zhu,Hui-Qing, AU - Zhuang,Zi-Ming, AU - Shao,Meng, AU - Chen,Fei-Long, AU - Liu,Chang-Shun, AU - Tang,Qing-Fa, Y1 - 2022/02/01/ PY - 2021/11/09/received PY - 2022/01/15/revised PY - 2022/01/27/accepted PY - 2022/2/6/pubmed PY - 2022/3/15/medline PY - 2022/2/5/entrez KW - Hehuan Yin decoction KW - In vivo experimental validation KW - Molecular docking KW - Network pharmacology KW - Polycystic ovary syndrome with insulin resistance SP - 115057 EP - 115057 JF - Journal of ethnopharmacology JO - J Ethnopharmacol VL - 289 N2 - ETHNOPHARMACOLOGICAL RELEVANCE: Hehuan Yin decoction (HHY), first recorded in the Jingyue Quanshu (published in 1624 A.D.), is composed of Albizia julibrissin Durazz. and Ampelopsis japonica (Thunb.) Makino. AIM OF THE STUDY: This study aimed to investigate the mechanism of action of HHY in treating polycystic ovary syndrome with insulin resistance (PCOS-IR). MATERIALS AND METHODS: Network pharmacology and molecular docking were used to predict active compounds, potential targets, and pathways for PCOS-IR treatment using HHY. Female Sprague-Dawley rats were administered letrozole (1 mg/kg) with a high-fat diet to establish a PCOS-IR model. Thereafter, symptoms, ovarian pathology, serum insulin resistance, and sex hormone levels were determined. Western blotting was used to determine the levels of PI3Kp85α, AKT, phospho (p)-AKT, and GSK3β in the ovaries of rats. RESULTS: Network pharmacology revealed 58 components in HHY and 182 potential targets that were shared between HHY and PCOS-IR. HHY could potentially treat PCOS-IR via the insulin resistance, PI3K/AKT, HIF-1, and steroid hormone biosynthesis pathways. Molecular docking revealed that PI3K, AKT1, GSK3β, IRS1, and EGFR had high affinities to HHY compounds. In the PCOS-IR rats, HHY significantly normalised the symptoms and ovarian pathology, increased follicle-stimulating hormone (FSH) and oestradiol levels in the serum, and decreased the levels of fasting plasma glucose and fasting insulin, as well as the insulin resistance index. HHY also decreased the luteinising hormone (LH) and testosterone levels and the LH/FSH ratio in the PCOS-IR rats and increased the levels of PI3K, p-AKT, and GSK3β in ovary tissue, which indicated the activation of the PI3K/AKT pathway. CONCLUSIONS: HHY can improve PCOS-IR symptoms via multiple pharmacological pathways and may be a potential alternative therapy for the treatment of PCOS-IR. SN - 1872-7573 UR - https://www.unboundmedicine.com/medline/citation/35121050/Network_pharmacology_integrated_with_experimental_validation_reveals_the_regulatory_mechanism_of_action_of_Hehuan_Yin_decoction_in_polycystic_ovary_syndrome_with_insulin_resistance_ DB - PRIME DP - Unbound Medicine ER -

Tags

Network pharmacology integrated with experimental validation reveals the regulatory mechanism of action of Hehuan Yin decoction in polycystic ovary syndrome with insulin resistance.J Ethnopharmacol. 2022 May 10; 289:115057.JE